Pharmacogenetic Study of Bisoprolol in Egyptian Patients With Acute Coronary Syndrome

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 127 participants.

Also called NCT05536271

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 127 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05536271
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05536271. Allocation not applicable; no masking; primary purpose treatment. Start 2021-09-01 (actual); primary completion 2022-06-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Pharmacogenetic Study of Bisoprolol in Egyptian Patients With Acute Coronary Syndrome
Condition
Acute Coronary Syndrome
Intervention (Drug)
Bisoprolol Fumarate
Lead sponsor
Damanhour University (class: other)
Collaborator
Alexandria University (class: other)

Record details

Record id
cardio:ct-nct05536271
Content hash
d6280ae4b9071dca8ff8a82f8c98b9b3791f40e1978035e474dd85c993a1c597